Study S003377

A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Id/IIa Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov record

Registration

Registration: NCT07065032
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 27
Start: 2024-02-19
Primary completion: 2024-07-22
Lead sponsor: Beijing QL Biopharmaceutical Co.,Ltd
Conditions: Type 2 Diabetes
Interventions: DRUG:ZT002 Injection; DRUG:ZT002 Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of treatment emergent adverse events and serious adverse events; Number of participants with injection site reaction. [up to 155days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.